For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Upadacitinib - Atopic dermatitis
PAD Profile : Upadacitinib - Atopic dermatitis
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
Other Indications
- Rheumatoid arthritis
- Psoriatic arthritis
- Non-radiographic axial spondyloarthritis
- Ankylosing spondylitis
- Inflammatory bowel disease
Additional Documents
Committee Recommendations
The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed the updated Atopic Dermatitis treatment pathway
The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) has agreed the use of Abrocitinib, tralokinumab and upadacitinib for the treatment of moderate to severe atopic dermatitis in line with NICE TA814
Abrocitinib, tralokinumab and upadacitinib will be given a RED traffic light status. Prescribing will be by hospital specialists only, in line with NICE TA814
Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.